Russia's ChemRar gets rights to Pfizer's DPP-IVi diabetes candidate

6 July 2012

Russia’s ChemRar Hi-Tech Centre, a pharmaceutical investment and R&D group, said yesterday that global drugs behemoth Pfizer (NYSE: PFE) has granted exclusive development and marketing rights to SatRx for its DPP(1)-IVi compound, PF-00734200.

SatRX, a ChemRar group company, is developing PF-00734200 for type 2 diabetes, one of the most burdensome chronic non-communicable diseases, which is fast reaching epidemic proportions throughout the world.

Under the terms of the license, signed during the St Petersburg Economic Forum last month, Pfizer granted exclusive worldwide rights (ex-China) development and commercialization of PF-00734200 as monotherapy or in combination with certain other therapies. Pfizer will receive undisclosed royalties and milestone payments based on commercialization activities. The agreement was developed as partial fulfillment of a Memorandum of Understanding reached last year (The Pharma Letter July 1, 2011), under which Pfizer and ChemRar agreed to explore collaborations focused on research, development and commercialization of innovative compounds and vaccines to treat cardiometabolic, infectious and oncologic diseases in Russia and other countries.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical